Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study

British Journal of Dermatology

Volumn 175, Issue 3, 2016, Pages 487-492

  Egeberg, A ^a   Mallbris, L ^b   Warren, R B ^c   Bachelez, H ^d   Gislason, G H ^a,e,f   Hansen, P R ^a   Skov, L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Universite de Paris Diderot   (France)

^e Department of Cardiovascular Epidemiology and Research   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CROHN DISEASE; DANISH CITIZEN; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POISSON DISTRIBUTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RISK ASSESSMENT; ULCERATIVE COLITIS;

EID: 84987794560     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14528     Document Type: Article

References (37)

1. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol 2014; 7:119–32.
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370:263–71.
3. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129:1339–50.
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361:2066–78.
5. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461–3.
6. Ellinghaus D, Ellinghaus E, Nair RP et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012; 90:636–47.
7. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80:273–90.
8. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8:458–66.
9. Skroza N, Proietti I, Pampena R et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int 2013; 2013:983902.
10. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23:561–5.
11. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2013; 72:1200–5.
12. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990; 85:962–3.
13. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982; 106:323–30.
14. Tsai TF, Wang TS, Hung ST et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63:40–6.
15. Edson-Heredia E, Zhu B, Lefevre C et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol 2015; 29:955–63.
16. Wu JJ, Nguyen TU, Poon KY, Herrington LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol 2012; 67:924–30.
17. Augustin M, Reich K, Glaeske G et al. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90:147–51.
18. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453–7.
19. Andersen TF, Madsen M, Jørgensen J et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46:263–8.
20. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44:445–8.
21. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health 2011; 39:103–5.
22. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29:541–9.
23. Egeberg A, Mallbris L, Gislason GH et al. Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol 2015; 136:93–8.
24. Ahlehoff O, Gislason GH, Charlot M et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270:147–57.
25. Fonager K, Sørensen HT, Rasmussen SN et al. Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system. Scand J Gastroenterol 1996; 31:154–9.
26. Egeberg A, Mallbris L, Hilmar Gislason G et al. Increased risk of migraine in patients with psoriasis: a Danish nationwide cohort study. J Am Acad Dermatol 2015; 73:829–35.
27. van der Heide F, Dijkstra A, Weersma RK et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009; 15:1199–207.
28. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol 2014; 170:304–14.
29. Cosnes J. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis 2010; 28:411–17.
30. Anderson CA, Boucher G, Lees CW et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43:246–52.
31. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36:542–50.
32. Rovedatti L, Kudo T, Biancheri P et al. Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. Gut 2009; 58:1629–36.
33. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223:87–113.
34. Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res 2014; 2014:283617.
35. Vanhove W, Nys K, Vermeire S. Therapeutic innovations in inflammatory bowel diseases. Clin Pharmacol Ther 2016; 99:49–58.
36. Musso A, Dentelli P, Carlino A et al. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis 2005; 11:91–8.
37. Papp KA, Menter MA, Abe M et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015; 173:949–61.